STOCK TITAN

Ultragenyx to Participate in the Jefferies London Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) CEO to participate in fireside chat at Jefferies London Healthcare Conference on November 14, 2023. The company focuses on developing therapies for rare genetic diseases. Webcast accessible at company website.
Positive
  • None.
Negative
  • None.

NOVATO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on Tuesday, November 14, 2023, at 12:30 p.m. GMT.

The live and archived webcast of the panel will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com

Media
Jeff Blake
media@ultragenyx.com


FAQ

What is the event Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) CEO will participate in?

The CEO will participate in a fireside chat at the Jefferies London Healthcare Conference.

What is the focus of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)?

The company is focused on developing and commercializing novel therapies for serious rare and ultrarare genetic diseases.

Where can the webcast of the panel be accessed?

The live and archived webcast will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.

Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

RARE Rankings

RARE Latest News

RARE Stock Data

4.01B
88.07M
3.62%
97.49%
3.62%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NOVATO